Stock Events

Stock Events

Search...

Evolus

$16.09

27

-$0.15-0.92% Today

Statistics

Day High

16.33

Day Low

15.89

52W High

17.82

52W Low

7.44

Volume

220,531

Avg. Volume

592,106

Mkt Cap

1B

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

5NovExpected

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

Q2 2024

Next

-0.32

-0.23

-0.13

-0.04

Expected EPS

-0.1237

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EOLS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Merck & Co., through its acquisition of companies and products, competes in the aesthetics and dermatology space, potentially overlapping with Evolus's market.

GlaxoSmithKline, a large pharmaceutical company, has a diverse portfolio that includes products competing in the aesthetics space.

Pfizer, with its broad range of healthcare products, competes in various segments, including those that overlap with Evolus's interests.

AbbVie, after acquiring Allergan, directly competes with Evolus in the cosmetic injectable market, particularly with its Botox product.

SPDR SSgA Global Allocation

Galderma, a company specializing in dermatological treatments, offers a range of products that compete in the same space as Evolus's offerings.

Revolve, while primarily known for its fashion retail, has ventured into beauty and skincare products that could indirectly compete with Evolus.

Johnson & Johnson

Johnson & Johnson, through its wide range of healthcare products, has interests in the dermatology and aesthetics market, competing with Evolus.

Teva- Pharmaceutical Industries

Teva Pharmaceutical Industries, with its generic and specialty medicines, competes in the broader pharmaceutical market, including areas relevant to Evolus.

Novartis, a global healthcare company, has a diverse portfolio that includes dermatology and aesthetics, competing with Evolus in certain markets.

Analyst Ratings

23$Average Price Target

The highest estimate is $27.

From 4 ratings within the last 6 months. This is not an investment recommendation.

Buy

100%

Hold

0%

Sell

0%

About

Health Technology

Pharmaceuticals: Major

Manufacturing

Medicinal and Botanical Manufacturing

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Show more...

CEO

David Moatazedi

Employees

304

Country

US

ISIN

US30052C1071

Listings